Effects of edoxaban: A Synthesis of Findings from 27 Studies

  1. Home
  2. Effects of edoxaban
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of edoxaban: A Synthesis of Findings from 27 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of edoxaban: A Synthesis of Findings from 27 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Research on the effects of edoxaban has shown promising results in terms of its effectiveness and safety compared to warfarin in preventing stroke and treating venous thromboembolism (VTE) in patients with atrial fibrillation. 3 highlights that while edoxaban has proven antithrombotic effects, its long-term efficacy and safety compared to warfarin in patients with atrial fibrillation remains unknown. 24 projects an increase in the number of Europeans with atrial fibrillation (AF) in the coming decades due to the aging population, which would also lead to an increase in strokes. The study suggests that the use of vitamin K antagonists (VKAs, such as warfarin) can reduce the risk of thromboembolism (primarily stroke and systemic embolism) and death, with non-VKA oral anticoagulants (NOACs) like edoxaban demonstrating even greater efficacy. 11 suggests that edoxaban might be effective in preventing blood clots but carries a lower risk of bleeding than warfarin based on a meta-analysis of phase III randomized controlled trials comparing edoxaban to vitamin K antagonists (VKAs). A case report in 15 demonstrates edoxaban preventing adverse effects like fever and D-dimer elevation caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma. 26 investigated the effectiveness of a foot pump in reducing the incidence of deep vein thrombosis (DVT) after total knee arthroplasty (TKA) in patients receiving edoxaban for thromboprophylaxis through a randomized clinical trial. The results indicated that the foot pump did not significantly reduce DVT incidence in patients undergoing TKA under edoxaban thromboprophylaxis. 27 delves into regional differences in Asia and compares edoxaban’s effects with warfarin in Japan and the rest of East Asia, including China, Korea, and Taiwan, based on the ENGAGE AF-TIMI 48 trial. 16 analyzes the blood coagulation status during cryoballoon ablation, a common treatment for atrial fibrillation, and examines the effects of direct anticoagulants like dabigatran and edoxaban. 21 outlines the rationale and design of the ENVISAGE-TAVI AF trial, which compares edoxaban with standard of care and their effects on clinical outcomes in patients who have undergone transcatheter aortic valve implantation (TAVR) for atrial fibrillation. 17 focuses on the effects of edoxaban and warfarin on vascular remodeling, particularly the progression of atherosclerotic plaque and collateral artery growth. 10 investigates the effects of edoxaban on the cellular and protein phases of coagulation in patients with coronary artery disease receiving dual antiplatelet therapy with aspirin and clopidogrel. 5 presents a systematic review of current research on laboratory measurement of the anticoagulant activity of edoxaban. 19 demonstrates that edoxaban exhibits antioxidant effects through FXa inhibition and direct radical-scavenging activity. 4 examines the effects of edoxaban on bleeding after a punch biopsy and its reversal by a 4-factor prothrombin complex concentrate. 1 details a clinical safety, tolerability, pharmacokinetics, and pharmacodynamics study of edoxaban in healthy volunteers. 25 shows that a single dose of ciraparantag safely and completely reverses the anticoagulant effects of edoxaban. 14 focuses on the development, characterization, and effects of inhaled edoxaban dry powder inhaler formulations on the coagulopathy associated with COVID-19 infection. 2 evaluates the effects of antiplatelet agents like aspirin and naproxen on the pharmacokinetics and pharmacodynamics of edoxaban. 9 analyzes the impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism. 12 examines the effects of anticoagulants in patients with atrial fibrillation at extreme body weights. 7 compares the efficacy and safety of edoxaban and warfarin in nonvalvular atrial fibrillation. 13 reviews the pleiotropic effects of NOACs, focusing on edoxaban. 8 summarizes evidence on laboratory assessment of the anticoagulant effects of direct oral anticoagulants (DOACs). 6 examines the impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of edoxaban. 23 demonstrates that andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding. 22 compares the effects of edoxaban on venous thromboembolism between patients with and without cancer. 20 investigates the effects of edoxaban on routine coagulation assays, lupus anticoagulant, and anti-Xa assays.

Benefits and Risks

Benefits Summary

Edoxaban has shown promise as a potential alternative to warfarin, offering benefits such as greater efficacy and safety in preventing stroke and treating venous thromboembolism in patients with atrial fibrillation. 3 , 7 , 24 , 9 Additionally, edoxaban is considered easier to manage compared to warfarin, making it a more convenient option for patients. 8 Research suggests that edoxaban might have antioxidant effects, potentially helping to slow down the progression of kidney disease. 19 Overall, edoxaban emerges as a viable treatment option for various conditions including atrial fibrillation, venous thromboembolism, and cancer-associated VTE. 22

Risks Summary

While edoxaban is associated with a lower risk of bleeding compared to warfarin, the risk of bleeding still exists. 7 , 11 As a newer medication, edoxaban has limited long-term safety data. 3 Furthermore, edoxaban can cause gastrointestinal side effects in some patients. 1 It is crucial to consult with your doctor and carefully weigh the risks and benefits of edoxaban before using it.

Comparison Between Studies

Commonalities

Several studies indicate that edoxaban demonstrates greater efficacy and safety compared to warfarin in preventing stroke and treating venous thromboembolism in patients with atrial fibrillation. 3 , 7 , 24 , 9 , 11 , 22 However, there is some inconsistency among these studies regarding the conclusion that edoxaban carries a lower risk of bleeding compared to warfarin. 11 Moreover, long-term safety and efficacy data on edoxaban remains limited. 3 These studies suggest that the effects of edoxaban can be effectively reversed in various situations. 4 , 25 , 23 The anticoagulant effect of edoxaban can be measured using different coagulation tests. 5 , 8 , 20 These studies highlight that edoxaban can be a viable treatment option for various conditions like atrial fibrillation, venous thromboembolism, and cancer-associated VTE. 22 Additionally, they indicate that edoxaban’s effectiveness might be influenced by patient factors like age, comorbidities, and polypharmacy. 9 , 12

Differences

There is inconsistency among the studies concerning the conclusion that edoxaban carries a lower risk of bleeding compared to warfarin. 11 Long-term safety and efficacy data on edoxaban remains limited. 3 There is no clear consensus on the best method to reverse the effects of edoxaban. 4 , 25 , 23 Several studies suggest that edoxaban’s effectiveness might be influenced by patient factors like age, comorbidities, and polypharmacy. 9 , 12 The research on edoxaban’s effectiveness is promising, but more research is needed to address these inconsistencies.

Consistency and Discrepancies in Results

While the research on the effects of edoxaban presents numerous results supporting its efficacy and safety, some studies show discrepancies regarding the risk of bleeding. 11 These discrepancies might be attributed to variations in patient populations and research designs. 9 , 12 Furthermore, long-term safety and efficacy data on edoxaban is limited. 3 Therefore, larger and longer-term studies are needed to address these discrepancies and gain a more comprehensive understanding of edoxaban’s long-term effects.

Important Considerations for Real-World Applications

Edoxaban has shown potential as a viable alternative to warfarin in preventing stroke and treating venous thromboembolism in patients with atrial fibrillation. 3 , 7 , 24 , 9 However, there is no clear consensus on whether edoxaban carries a lower risk of bleeding compared to warfarin. 11 Therefore, it is vital to consult with your doctor to discuss the potential risks of bleeding and other side effects before taking edoxaban. 1 Moreover, edoxaban’s effectiveness might be influenced by patient factors like age, comorbidities, and polypharmacy. 9 , 12 Doctors should consider these factors when recommending medication to patients.

Limitations of Current Research

Many studies on the effects of edoxaban have been conducted over relatively short periods, resulting in limited long-term safety and efficacy data. 3 Furthermore, these studies have employed diverse patient populations and research designs, making it challenging to compare their results. 9 , 12 There is no clear consensus on the most effective method to reverse the effects of edoxaban. 4 , 25 , 23 While some studies suggest that edoxaban can be effectively reversed in various situations, further research is needed to confirm and establish the optimal methods for reversing its effects.

Future Research Directions

Larger and longer-term studies are necessary to gain a more comprehensive understanding of the long-term safety and efficacy of edoxaban. 3 Long-term safety and efficacy data on edoxaban is still limited, highlighting the need for extended research. 3 Comparative studies examining edoxaban’s effects in various patient populations are also essential. 9 , 12 Establishing the most effective methods to reverse the anticoagulant effects of edoxaban is crucial. 4 , 25 , 23 These research endeavors are essential to solidify edoxaban’s position as a reliable treatment option and address any uncertainties surrounding its application.

Conclusion

Edoxaban holds promise as a potentially effective alternative to warfarin in preventing stroke and treating venous thromboembolism in patients with atrial fibrillation. 3 , 7 , 24 , 9 However, there is no definitive agreement on whether edoxaban carries a lower risk of bleeding compared to warfarin. 11 It is vital to discuss the risks of bleeding and other side effects with your doctor before taking edoxaban. 1 Additionally, be aware that edoxaban’s effectiveness might be influenced by factors like age, comorbidities, and polypharmacy. 9 , 12 Doctors need to consider these factors when making treatment decisions for patients. Ultimately, further research is crucial to address inconsistencies and provide a more comprehensive understanding of edoxaban’s long-term effects and the best methods for reversing its anticoagulation effect.

Literature analysis of 27 papers
Positive Content
25
Neutral Content
1
Negative Content
1
Article Type
13
2
2
3
27
1.

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.

Author: OgataKoichiro, Mendell-HararyJeanne, TachibanaMasaya, MasumotoHiroshi, OgumaToshihiro, KojimaMasazumi, KunitadaSatoshi

Predictable PK and PD profiles
Safe and well tolerated

Single and multiple doses of edoxaban, an oral direct factor Xa inhibitor, were safe and well tolerated in healthy males up to 150 mg.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.

Author: MendellJeanne, LeeFrank, ChenShuquan, WorlandValerie, ShiMinggao, SamamaMeyer M

Stroke prevention

Edoxaban is a blood thinner used to prevent stroke in patients with atrial fibrillation. This study investigates the interactions between edoxaban and aspirin or naproxen, which are commonly taken by elderly patients.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Edoxaban versus warfarin in patients with atrial fibrillation.

Author: GiuglianoRobert P, RuffChristian T, BraunwaldEugene, MurphySabina A, WiviottStephen D, HalperinJonathan L, WaldoAlbert L, EzekowitzMichael D, WeitzJeffrey I, ŠpinarJindřich, RuzylloWitold, RudaMikhail, KoretsuneYukihiro, BetcherJoshua, ShiMinggao, GripLaura T, PatelShirali P, PatelIndravadan, HanyokJames J, MercuriMichele, AntmanElliott M,

Reduced bleeding
Reduced cardiovascular death
Stroke prevention
None reported

This randomized controlled trial compared two once-daily regimens of edoxaban, a direct oral factor Xa inhibitor, with warfarin in patients with moderate-to-high-risk atrial fibrillation. The study found that both edoxaban regimens were noninferior to warfarin in preventing stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.

Author: ZahirHamim, BrownKaren S, VandellAlexander G, DesaiMadhuri, MaaJen-Fue, DishyVictor, LomeliBarbara, FeussnerAnnette, FengWenqin, HeLing, GrossoMichael A, LanzHans J, AntmanElliott M

Bleeding

Edoxaban is a blood thinner (anticoagulant) used to prevent stroke and blood clots. This study investigated the ability of a 4-factor prothrombin complex concentrate (4F-PCC) to reverse the effects of edoxaban.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.

Author: CukerAdam, HusseinzadehHolleh

Stroke prevention
Systemic embolism prevention
VTE treatment

Edoxaban, an oral factor Xa inhibitor, is approved for stroke and systemic embolism prevention in non-valvular atrial fibrillation and venous thromboembolism treatment. This review summarizes the evidence on laboratory measurement of edoxaban's anticoagulant activity, highlighting the relationship between coagulation tests and plasma edoxaban levels. While anti-Xa activity is a good indicator, more data is needed to understand the relationship between drug levels, coagulation tests, and clinical outcomes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

6.

The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.

Author: BrownKaren S, WickremasinghaPrachi, ParasrampuriaDolly A, WeissDaniel, KochanJarema, DishyVictor, HeLing, ShiMinggao

Anticoagulation reversal
Not specified

This study evaluated the ability of a 3-factor prothrombin complex concentrate (3F-PCC) to reverse the anticoagulatory effects of edoxaban, a direct factor Xa inhibitor.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.

Author: ChenJunyu, ZhuangXiaodong, LongMing, SuChen, WangLichun

Prevents thromboembolism

Edoxaban, an alternative to warfarin for preventing thromboembolism in atrial fibrillation, showed comparable efficacy and safety but with potential dosage-dependent effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : English

8.

Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.

Author: SamuelsonBethany T, CukerAdam, SiegalDeborah M, CrowtherMark, GarciaDavid A

Treatment of choice for atrial fibrillation
Treatment of choice for venous thromboembolic disease

Direct oral anticoagulants (DOACs) are the treatment of choice for most patients with atrial fibrillation and/or noncancer-associated venous thromboembolic disease. This review summarizes systematically evidence regarding laboratory assessment of the anticoagulant effects of dabigatran, rivaroxaban, apixaban, and edoxaban.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

9.

Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.

Author: VanasscheThomas, VerhammePeter, WellsPhilip S, SegersAnnelise, AgenoWalter, BrekelmansMarjolein P A, ChenCathy Z, CohenAlexander T, GrossoMichael A, MedinaAndria P, MercuriMichele F, WintersShannon M, ZhangGeorge, WeitzJeffrey I, RaskobGary E, BüllerHarry R

VTE treatment

This analysis compared the efficacy and safety of edoxaban and warfarin in patients with venous thromboembolism (VTE) considering factors like advanced age, comorbidities, and polypharmacy. The study aimed to address the lack of comparative data for DOACs and warfarin in elderly patients with multiple comorbidities.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.

Author: FranchiFrancesco, RolliniFabiana, GarciaEmilio, Rivas RiosJose, RivasAndrea, AgarwalMalhar, KuretiMegha, NagarajuDeepa, WaliMustafa, BricenoMaryuri, MoonJae Youn, KairouzVictor, YaranovDmitry, BeenLatonya, SuryadevaraSiva, SofferDaniel, ZenniMartin M, BassTheodore A, AngiolilloDominick J

Reduced bleeding risk

In patients requiring dual antiplatelet therapy (DAPT) who also have an indication to be treated with oral anticoagulant (OAC) drugs, aspirin withdrawal reduces the risk of bleeding.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

11.

The risk of bleeding and all-cause mortality with edoxaban versus vitamin K antagonists: A meta-analysis of phase III randomized controlled trials.

Author: ChenHai-Bin, XiuJiancheng, LiYu-Hui, YuTian-Hao

Reduced bleeding risk

This study found that compared to vitamin K antagonists (VKAs), edoxaban is safe as a direct oral anticoagulant, with respect to reduced risk of major or clinically relevant nonmajor bleeding (CRNM), intracranial bleeding events, and similar risk of gastro-intestinal bleeding events and all-cause mortality.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : English

12.

Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial.

Author: BorianiGiuseppe, RuffChristian T, KuderJulia F, ShiMinggao, LanzHans J, AntmanElliott M, BraunwaldEugene, GiuglianoRobert P

Anticoagulation effect

This study analyzes the pharmacokinetics/pharmacodynamics and clinical outcomes of warfarin, higher dose edoxaban (HDER), and lower dose edoxaban (LDER) regimens in patients with extremes of body weight (BW).

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

13.

Pleiotropic effects of NOACs with focus on edoxaban: scientific findings and potential clinical implications.

Author: GoetteAndreas, MollenhauerMartin, RudolphVolker, LamparterMathias, MeierMartin, BöhmMichael

Thrombosis prevention

This review discusses potential pleiotropic effects of edoxaban, a factor Xa inhibitor, beyond its anticoagulant properties. It highlights the role of factor Xa and thrombin in activating protease-activated receptors (PARs), which contribute to inflammation and fibrosis. Studies suggest that edoxaban may attenuate these pro-inflammatory and pro-fibrotic effects, potentially contributing to its beneficial outcomes in cardiovascular disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

15.

Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.

Author: MukaiKei, KamataMasahiro, MiyazakiMirei, NagataMayumi, FukayaSaki, HayashiKotaro, FukuyasuAtsuko, IshikawaTakeko, OhnishiTakamitsu, TadaYayoi, TanakaTakamitsu

Melanoma treatment
D-dimer elevation
Pyrexia

This case report describes a patient with BRAF-mutated melanoma who experienced elevated D-dimer levels and pyrexia after CombiDT and CombiEB treatments. Concomitant edoxaban prevented these adverse events, allowing the patient to continue receiving CombiEB.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

Effects of edoxaban and warfarin on vascular remodeling: Atherosclerotic plaque progression and collateral artery growth.

Author: MillenaarDominic, BachmannPhilipp, BöhmMichael, CustodisFlorian, SchirmerStephan H

Thromboembolism prevention

This study aims to evaluate the influence of edoxaban compared to warfarin on vascular remodeling, atherosclerosis, and arteriogenesis in patients with atrial fibrillation.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.

Author: FranchiFrancesco, RolliniFabiana, GarciaEmilio, Rivas RiosJose, RivasAndrea, AgarwalMalhar, KuretiMegha, NagarajuDeepa, WaliMustafa, BricenoMaryuri, MoonJae Youn, KairouzVictor, YaranovDmitry, BeenLatonya, SuryadevaraSiva, SofferDaniel, ZenniMartin M, BassTheodore A, AngiolilloDominick J

Reduced bleeding risk

In patients requiring dual antiplatelet therapy (DAPT) who also have an indication to be treated with oral anticoagulant (OAC) drugs, aspirin withdrawal reduces the risk of bleeding.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

19.

Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity.

Author: NaritaYuki, HamamuraKana, KashiyamaMami, UtsumiSara, KakizoeYutaka, KondoYuki, IshitsukaYoichi, JonoHirofumi, IrieTetsumi, MukoyamaMasashi, SaitoHideyuki, KadowakiDaisuke, HirataSumio, KitamuraKenichiro

CKD treatment
Oxidative stress reduction

Edoxaban, an activated blood coagulation factor Xa (FXa) inhibitor, ameliorates kidney disease by suppressing inflammation and tissue fibrosis in animal models.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

21.

Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.

Author: Van MieghemNicolas M, UnverdorbenMartin, ValgimigliMarco, MehranRoxana, BoersmaEric, BaberUsman, HengstenbergChristian, ShiMinggao, ChenCathy, SaitoShigeru, VeltkampRoland, VranckxPascal, DangasGeorge D

Reduced bleeding
Reduced cardiovascular death
Stroke prevention

The ENVISAGE-TAVI AF study compares edoxaban, a direct factor Xa inhibitor, to vitamin K antagonists (VKAs) in patients with atrial fibrillation after transcatheter aortic valve replacement (TAVR) to determine the effectiveness and safety of each treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.

Author: IkedaSatoshi, KogaSeiji, YamagataYuki, EguchiMasamichi, SatoDaisuke, MuroyaTakahiro, YonekuraTsuyoshi, TsunetoAkira, YoshimutaTsuyoshi, KoideYuji, KawanoHiroaki, MaemuraKoji

VTE treatment

Edoxaban, an oral direct factor Xa inhibitor, is an alternative to low-molecular weight heparin for the treatment of venous thromboembolism in cancer patients.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

23.

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.

Author: LuGenmin, PinePolly, LeedsJanet M, DeGuzmanFrancis, PratikhyaPratikhya, LinJoyce, MalinowskiJohn, HollenbachStanley J, CurnutteJohn T, ConleyPamela B

Bleeding management

Andexanet alfa rapidly reversed the anticoagulant effects of edoxaban in vitro and reduced bleeding in rabbits.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives.

Author: BlannAndrew D, BorianiGiuseppe, LipGregory Y H

Effective anticoagulant
Reduces stroke risk

This article discusses the increasing prevalence of atrial fibrillation (AF) and the associated risk of stroke. It highlights the benefits of oral anticoagulants, particularly non-vitamin K antagonist oral anticoagulants (NOACs), in reducing the risk of thromboembolism in patients with AF.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

25.

Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban.

Author: AnsellJack E, BakhruSasha H, LaulichtBryan E, SteinerSolomon S, GrossoMichael A, BrownKaren, DishyVictor, LanzHans J, MercuriMichele F, NoveckRobert J, CostinJames C

Reverses anticoagulation
Cool sensation
Flushing

Ciraparantag is a novel reversal agent for direct factor Xa inhibitors, a class of oral anticoagulants. This study investigated the safety, tolerability, and impact of ciraparantag on anticoagulation reversal in healthy subjects. Ciraparantag was found to be safe and well-tolerated, effectively reversing the anticoagulant effects of edoxaban within 10 minutes.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

26.

Effects of a Foot Pump on the Incidence of Deep Vein Thrombosis After Total Knee Arthroplasty in Patients Given Edoxaban: A Randomized Controlled Study.

Author: SakaiTatsuya, IzumiMasahiro, KumagaiKenji, KideraKenichi, YamaguchiTakayuki, AsaharaTomohiko, KozuruHideko, JiuchiYuka, MawatariMasaaki, OsakiMakoto, MotokawaSatoru, MigitaKiyoshi

Deep-vein thrombosis

The A-V Impulse System foot pump did not reduce the incidence of deep-vein thrombosis in patients undergoing total knee arthroplasty under edoxaban thromboprophylaxis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

27.

Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin--Insights From the ENGAGE AF-TIMI 48 Trial.

Author: ShimadaYuichi J, YamashitaTakeshi, KoretsuneYukihiro, KimuraTetsuya, AbeKenji, SasakiShunichi, MercuriMichele, RuffChristian T, GiuglianoRobert P

Effective thromboembolism prevention
Reduced bleeding
Higher-dose edoxaban less effective in Japan

Higher-dose edoxaban had greater efficacy and safety in East Asia than in Japan, which was not fully explained by differences in baseline characteristics and time-in-therapeutic range.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.